Advertisement
Research Article

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  • William Pao mail,

    To whom correspondence should be addressed. E-mail: paow@mskcc.org

    Affiliations: Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Theresa Y Wang,

    Affiliation: Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Gregory J Riely,

    Affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Vincent A Miller,

    Affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Qiulu Pan,

    Affiliation: Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Marc Ladanyi,

    Affiliation: Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Maureen F Zakowski,

    Affiliation: Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Robert T Heelan,

    Affiliation: Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Mark G Kris,

    Affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Harold E Varmus

    Affiliation: Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Published: January 25, 2005
  • DOI: 10.1371/journal.pmed.0020017

Viewed info

Cited info

Saved info

Discussed info

Questions or concerns about usage data? Please let us know.